We have reported that CPAP treatment improved the walking capacity of overlap syndrome patients. However, the previous study was not randomized, double blinded study. Therefore, we design a prospective, randomized, double blinded, controlled, cross-over trial to confirm this finding.
inclusion criteria : * COPD : FEV1/FVC \< 70%, no response to bronchodilator (FEV1 change \<12% and \<200ml) * OSA : AHI \> 15/h, obstructive type predominant exclusion criteria : * any malignancy * pregnancy * claustrophobia * age\<18 primary outcome : exercise capacity (walking distance (meter), measured by incremental shuttle walking test) Method : For those fit in criteria. CPAP titration will be performed to determine the optimal pressure Baseline measurement : incremental shuttle walking test, urine catecholamine, heart rate variability, muscle power and other baseline characteristics Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
Department of Thoracic Medicine, Chang Gung Memorial Hospital
Taipei, Taiwan
exercise capacity (walking distance (meter), measured by incremental shuttle walking test)
Time frame: CPAP treatment for 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.